RxDoctor Payments Data

Victoria Segro

Nurse Practitioner · Englewood, CONPI 1003800301

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (44.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by AbbVie at 35.6% of the total. Among nurse practitioner clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$29,254in general payments, 2019–2025

Across 494 payments — averaging $59.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$10K
  • Teva Pharmaceuticals USA, Inc.$7K
  • Acorda Therapeutics, Inc$4K
  • MDD US Operations, LLC$2K
  • UCB, Inc.$1K
  • Acadia Pharmaceuticals Inc$834
  • plus $3K from 23 others
$11,018in research payments, 2019–2025

Across 50 payments — averaging $220.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Neurocrine Biosciences, Inc.$11K

What the payments were for

  • Consulting fees$1,6756%
  • Speaking & faculty fees$12,86844%
  • Travel & lodging$2,1107%
  • Food & beverage$12,48143%
  • Education$1210%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,254 in reported general payments places this provider in the 95th percentile of 1,384 nurse practitioner providers in Colorado.

See all nurse practitioner providers in Colorado

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine24$169,206

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$6,692$169,20624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,384 nurse practitioner providers in Colorado.

Other nurse practitioner in Englewood

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →